AstraZeneca Egypt, global pharmaceutical industry leader, announced the approval by Egypt’s Ministry of Health and population and the Egyptian Drug Authority (EDA) after the approval of Food and Drug Administration (FDA) and European Medicines Agency (EMA) of the new indication of Forxiga (Dapagliflozin). The new indication works as a treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
This comes in line with AstraZeneca’s strategy to develop all of its medical services to offer the greatest benefit for the Egyptian patient, as the new indication of Forxiga (Dapagliflozin) reduces the complications that affect HF patients with reduced ejection fraction (HFrEF). HF is a life-threatening chronic disease, which prevents the heart from pumping sufficient levels of blood around the body parts, where half of HF patients suffer from reduced ejection fraction which occurs when the left ventricle muscle is not able to contract and therefore expels less oxygen-rich blood into the body.
On his part, Dr Hatem El-Werdany, Country President of AstraZeneca Egypt, stated “AstraZeneca’s efforts come within the framework of the company’s responsibility towards the patients and medical sector in Egypt, where we work hard to provide it with all the new and innovative solutions in the medical field. Furthermore, we invest our practical and medical capabilities to develop and support the medical field in Egypt in addition to working on easing the burden on the Egyptian patient by all possible means to ease their pain and give them hope in life.”
Dr El-Werdany also stressed that the new indication of Forxiga in this phase targeted HF patients. Yet, the scientific studies are continuing to examine the drug’s results for patients with chronic renal diseases.”
Dr Sherif Waguih, Medical Director of AstraZeneca Egypt, said: “We are proud to offer innovative health solutions to help HF patients with reduced ejection fraction (HFrEF), which usually causes high risks of increased death rates and hospitalisation. Today, we can confidently foresee that the addition of Forxiga (Dapagliflosin) will achieve a leap in the treatment of these patients globally and locally.
